KL 1333

Drug Profile

KL 1333

Alternative Names: KL 1333D; KL 1333M; KL1333

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KT&G Life Sciences
  • Developer Yungjin Pharm Co
  • Class Small molecules
  • Mechanism of Action Nicotinamide adenine dinucleotide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial disorders; MELAS syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mitochondrial disorders
  • Preclinical Diabetes mellitus

Most Recent Events

  • 21 May 2018 Adverse events and pharmacokinetics data from a phase I trial in Mitochondrial disorders released by NeuroVive Pharmaceutical
  • 21 May 2018 NeuroVive Pharmaceutical plans a phase II trial for Mitochondrial disorders
  • 21 May 2018 NeuroVive plans a complementary phase I trial for Mitochondrial disorders in Europe in second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top